<DOC>
	<DOCNO>NCT02285374</DOCNO>
	<brief_summary>This phase IV , open label , multicentre trial take place 4 site United Kingdom ( UK ) . Efavirenz take combination Kivexa® part combination pill , Atripla® recommend firstline regimen treatment Human Immunodeficiency Virus-1 ( HIV- 1 ) infection . Treatment HIV virus also refer antiretroviral therapy . Toxicity common reason modification firstline therapy . Central Nervous System ( CNS ) side effect difficulty sleep &amp; bad dreams common side effect Efavirenz base therapy one frequent reason switch discontinue highly active antiretroviral therapy . Dolutegravir within novel class antiretroviral agent license UK treatment HIV . In combination Truvada® , show few side effect compare Efavirenz clinical study , patient start HIV treatment first time , switch agent . The purpose study investigate benefit switch away Eefavirenz ( combination Kivexa® part combination pill , Atripla® ) Dolutegravir patient CNS side effect ( difficulty sleeping , bad dream etc ) .</brief_summary>
	<brief_title>Efavirenz Dolutegravir Switch Patients With CNS Toxicity</brief_title>
	<detailed_description>The main aim study investigate benefit switch Efavirenz ( take combination Kivexa®or part combination pill , Atripla® ) patient Central Nervous System ( CNS ) side effect ( difficulty sleeping , bad dream etc ) . The study aim investigate effect switch Efavirenz Dolutegravir continue Truvada ( tenofovir plus emtricitabine , two constituent Atripla ) Kivexa . Dolutegravir new component combination . In addition aim state , study also aim : To investigate whether switch dolutegravir base combination Antiretroviral Therapy ( cART ) associate resolution CNS toxicity ( determined CNS questionnaire ) 12 week post switch To investigate continued virological suppression level &lt; 400 &lt; 50 copies/ml individual switch dolutegravircontaining cART 4 12 week post switch To investigate change cluster differentiation 4+ ( CD4+ ) cell count individual switch dolutegravircontaining cART 12 week post switch To investigate safety ( laboratory non CNS adverse event ) switch dolutegravir base cART 12 week post switch To investigate change quality life individual switch dolutegravir base cART assess Quality life ( EuroQOL ) questionnaires 12 week post switch To investigate impact switch dolutegravir base CART anxiety depression ( determined Hospital Anxiety Depression Score ( HADS ) 12 week post switch To investigate change quality sleep individual switch dolutegravir base cART per standardized sleep questionnaire 4 12 week post switch To assess impact switch dolutegravir base cART adherence standard questionnaire 12 week post switch To investigate change neuropsychiatric function individual switch dolutegravir base cART CogState battery Instrumental Activities Daily Life ( IADL ) questionnaire 12 week post switch To investigate change fast cholesterol triglyceride individual switch dolutegravir base cART 12 weekspost switch To investigate Efavirenz ( EFV ) plasma decay impact Dolutegravir ( DTG ) concentration follow switch ( Maximum Concentration ( Cmax ) , Minimum Concentration ( Cmin ) , Area Under concentration-time Curve ( AUC ) week 1 , 2 3 post switch ) To investigate association genetic polymorphism drug disposition gene drug exposure To assess change level tryptophan , kynurenine , kynurenine/tryptophan ratio , neopterin , tumour necrosis factorα interferonγ plasma follow treatment switch efavirenz dolutegravir . To investigate relationship immune activation biomarkers kynurenine/tryptophan ratio baseline post switch . To investigate relationship kynurenine/tryptophan ratio measure CNS toxicity neurocognitive impairment baseline postswitch .</detailed_description>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Efavirenz , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>Is male female age 18 year old Has HIV1 infection document medical note Has sign Informed Consent Form voluntarily Is willing comply protocol requirement Is currently antiretroviral regimen comprise least three licensed antiretroviral agent one EFV , least 12 week No previous exposure integrase inhibitor Has HIVplasma viral load screen &lt; 400 copies/mL ( single retest allow ) Has CD4 cell count screen &gt; 50 cells/mm3 Estimated glomerular filtration rate ( MDRD ) &gt; 50 ml/min . Has symptomatic CNS related toxicity associate EFV least Grade 2 ACTG criterion If female childbearing potential , use effective birth control method ( agree investigator ) willing continue practise birth control method trial least 30 day end trial . Infected HIV2 Using concomitant therapy disallow per SPC study drug Has acute viral hepatitis include , limited , A , B , C Subjects positive Hepatitis B screening ( +HBsAg ) , anticipate need Hepatitis C virus ( HCV ) therapy study Alanine aminotransferase ( ALT ) great equal 5 time upper limit normal ( ULN ) , OR ALT great equal 3xULN bilirubin great equal 1.5xULN ( &gt; 35 % direct bilirubin ) Unstable liver disease ( define presence ascites , encephalopathy , coagulopathy , hypoalbuminemia , esophageal gastric varix , persistent jaundice ) , know biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) Any investigational drug within 30 day prior trial drug administration Has receive dolutegravir past Any clinical evidence baseline resistance mutation History presence allergy DTG excipients ( DMannitol , Microcystalline Cellulose , Povidone , Croscarmellose Sodium , Sodium Stearyl Fumarate , Talc , white film coat ) Subjects moderate severe hepatic impairment ( Class B great ) determine ChildPugh classification Moderate severe renal impairment ( creatinine clearance &lt; 50ml/min CockroftGault method ) If female , pregnant breastfeed Screening blood result grade 3/4 toxicity accord Division AIDS ( DAIDS ) grade scale , except : asymptomatic grade 3 glucose , amylase lipid elevation asymptomatic grade 4 triglyceride elevation ( retest allow ) . Any condition ( include drug/alcohol abuse ) laboratory result , investigator 's opinion , interfere assessment completion trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>